(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and Apoplexy

(e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide has been researched along with Apoplexy in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allahtavakoli, M; Arababadi, MK; Hajizadeh, MR; Hakimizadeh, E; Rahmani, MR; Roohbakhsh, A; Shamsizadeh, A; Shariati, M	1

Other Studies

1 other study(ies) available for (e)-3-(4-t-butylphenyl)-n-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide and Apoplexy

Article	Year
Inhibition of transient receptor potential vanilloid-1 confers neuroprotection, reduces tumor necrosis factor-alpha, and increases IL-10 in a rat stroke model. Fundamental & clinical pharmacology, 2017, Volume: 31, Issue:4 Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Interleukin-10; Male; Neuroprotective Agents; Rats; Rats, Wistar; Stroke; TRPV Cation Channels; Tumor Necrosis Factor-alpha	2017

Article

Year

Inhibition of transient receptor potential vanilloid-1 confers neuroprotection, reduces tumor necrosis factor-alpha, and increases IL-10 in a rat stroke model.

Fundamental & clinical pharmacology, 2017, Volume: 31, Issue:4

Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Interleukin-10; Male; Neuroprotective Agents; Rats; Rats, Wistar; Stroke; TRPV Cation Channels; Tumor Necrosis Factor-alpha

2017